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Abstract
Human cancers over-expressing mdm2, through a T to G variation at a single nucleotide polymorphism at position
309 (mdm2 SNP309), have functionally inactivated p53 that is not effectively degraded. They also have high
expression of the alternatively spliced transcript, mdm2-C. Alternatively spliced mdm2 transcripts are expressed in
many forms of human cancer and when they are exogenously expressed they transform human cells. However no
study to date has detected endogenous MDM2 protein isoforms. Studies with exogenous expression of splice
variants have been carried out with mdm2-A and mdm2-B, but the mdm2-C isoform has remained virtually
unexplored. We addressed the cellular influence of exogenously expressed MDM2-C, and asked if endogenous
MDM2-C protein was present in human cancers. To detect endogenous MDM2-C protein, we created a human
MDM2-C antibody to the splice junction epitope of exons four and ten (MDM2 C410) and validated the antibody with
in vitro translated full length MDM2 compared to MDM2-C. Interestingly, we discovered that MDM2-C co-migrates
with MDM2-FL at approximately 98 kDa. Using the validated C410 antibody, we detected high expression of
endogenous MDM2-C in human cancer cell lines and human cancer tissues. In the estrogen receptor positive (ER+)
mdm2 G/G SNP309 breast cancer cell line, T47D, we observed an increase in endogenous MDM2-C protein with
estrogen treatment. MDM2-C localized to the nucleus and the cytoplasm. We examined the biological activity of
MDM2-C by exogenously expressing the protein and observed that MDM2-C did not efficiently target p53 for
degradation or reduce p53 transcriptional activity. Exogenous expression of MDM2-C in p53-null human cancer cells
increased colony formation, indicating p53-independent tumorigenic properties. Our data indicate a role for MDM2-C
that does not require the inhibition of p53 for increasing cancer cell proliferation and survival.
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Introduction
The oncogenic activity of MDM2 is associated with over-
expression of the MDM2 protein in human cancers [1–3]. While
some MDM2 isoforms can form a direct physical association
with p53 others do not [3,4]. MDM2 regulates the p53 protein
through proteasomal-mediated degradation [5–10] and
transcriptional repression [5,11–14]. This p53-mediated
oncogenic activity of MDM2 is best referred to as MDM2
canonical functions. However, MDM2 is also known to possess
p53-independent functions [15–19] that are best referred to as
MDM2 non-canonical functions.
The over-expression of MDM2 due to a single nucleotide
polymorphism of thymine to guanine (T to G) at position 309 of
the MDM2 gene (mdm2 SNP309) is associated with increased
cancer incidence and aggressiveness [20–23]. This MDM2
SNP309 nucleotide change increases the binding affinity for
the constitutive transcription factor, Sp1 [21]. Cells
homozygous for the G/G mdm2 SNP309 have enhanced
mdm2 transcription and high MDM2 protein levels. MDM2 over-
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expression in cancers is often accompanied with the over-
expression of alternatively spliced mdm2 transcripts [3,24–28].
Over 40 alternatively and aberrantly spliced human mdm2
transcripts have been reported, however not all are the bone
fide result of alternative splicing events [29]. Not withstanding,
the mdm2 splice variants represent potential diversity that
agrees with the findings of the Encyclopedia of DNA Elements
(ENCODE) Project Consortium. ENCODE highlights previously
unrecognized candidate regulatory elements, and encoded
messages, in the human genome [30]. The diversity of mdm2
spliced messages encoded from two independent promoters
has the capacity to increase the human cancer proteome [31].
It is therefore not surprising that mdm2 SNP309 cells
demonstrate increased diversity in their alternatively spliced
mdm2 transcripts with substantial expression of the mdm2-C
transcript [32].
Although over 40 mdm2 alternatively spliced transcripts have
been identified [29], only five, (mdm2-A through mdm2-E) have
been shown to express protein in vitro [3]. The expression of
these five mdm2 transcripts causes NIH3T3 cells to form
tumor-associated foci [3]. However, only two protein isoforms,
MDM2-A and B, have been extensively studied for their
biological functions. The exogenous expression of MDM2-A
[33,34], or MDM2-B in mice [35], increases tumor formation in
a p53-null, or p53-compromised background causing an altered
tumor spectrum. However, the biological function of MDM2-C
remains undetermined.
We asked if cancer cells expressing high levels of mdm2-C
mRNA expressed endogenous MDM2-C protein. We
hypothesized that high mdm2-C transcript levels encoded from
the G allele mdm2 SNP309 in human cancers would result in
high levels of endogenous MDM2-C protein and would confer
oncogenic functions. Cells with MDM2 over-expression via the
G/G mdm2 SNP309 have stable p53 protein, which is co-
localized with p53 on the chromatin [14]. Thus, we
hypothesized that MDM2 over-expression via the G/G SNP309
might produce an MDM2-C protein isoform that would not
degrade p53. Therefore, we set out to determine the cellular
function of exogenously expressed MDM2-C. We also asked if
cancer cells expressing high levels of mdm2-C mRNA, also
expressed endogenous MDM2-C protein.
Endogenous expression of MDM2-C protein has never been
detected due to the absence of antibodies that specifically
detect the MDM2 isoforms made from the alternatively spliced
mRNAs. The mdm2-C transcript does not contain exons 5
through 9, which encodes a part of the p53-binding domain.
We created a specific antibody designed to detect the amino
acids encoded by MDM2-C flanking exons 4 and 10, which we
named C410. Using this MDM2 antibody we observed high
basal levels of endogenous MDM2-C protein in various MDM2
over-expressing cancer cell lines and tissues. We also
observed that, in the presence or absence of p53, exogenously
expressed MDM2-C promotes increased colony formation.
Taken together, our results indicate that endogenous MDM2-C
is expressed in cancers and that MDM2-C functions
independently of p53 to promote tumorigenesis.
Results
MDM2 over-expressing cells have high levels of mdm2-
C transcripts
Many human cancer cell lines over-express MDM2 protein
and have been used for previous MDM2 studies
[14,21,32,36,37]. We used these cell lines to examine the ratio
of mdm2-C transcripts to full-length mdm2 transcripts. The cell
lines examined include two high MDM2 expressors: SJSA-1
cells with wild-type p53 and over-expression of MDM2 due to
mdm2 gene amplification (and the mdm2 SNP309 T/T alleles)
and the MANCA cells with wild-type p53 and over-expression
of MDM2 from the mdm2 SNP309 G/G alleles. They also
include two low MDM2 expressors: the K562 cell line that is
p53-null and has an mdm2 SNP309 T/G alleles and the ML-1
cells with wild-type p53 and the mdm2 SNP309 T/T alleles.
Transcription of mdm2-C was assessed by quantitative
reverse transcription polymerase chain reaction (qRT-PCR)
and northern blot analysis (see Figure 1 and Figure S1).
Quantitation of total mdm2 transcripts, by northern blot
analysis, showed the highest level of mdm2 transcripts in
SJSA-1 cells, which contain 25 copies of the mdm2 gene [37].
A high level of mdm2 transcription was also observed in
MANCA cells. To specifically quantify transcripts containing
exons 6 and 7, we carried out qRT-PCR with a quantitative
probe to the exon 6-7 junction (Figure 1B see probe in green
and Figure 1C black bars). To specifically quantify mdm2-C
transcripts, we used a forward PCR primer designed to
recognize the exon 4, and exon 10, junction (called 4:10) and a
reverse primer to exon 12 (Figure 1B, see primers in red, and
Figure 1C grey bars). In MANCA cells, we detected low-level
expression of the mdm2 transcript containing exons 6 and 7,
from here on referred to as a mdm2 full-length transcript
(Figure 1C). Importantly, MANCA cells had high-level
expression of the mdm2-C transcript resulting in a lower ratio of
full-length to mdm2-C transcript (Figure 1C, MANCA compare
black to grey bar). This was in contrast to mdm2 transcription in
SJSA-1 cells, which produced similar levels of mdm2-C and
mdm2 full-length transcripts (Figure 1C, SJSA-1 compare black
to grey bars). Low levels of mdm2 transcripts were produced in
K562 cells and therefore these cells were used as the
normalizer cell line. ML-1 cells showed similar mdm2 transcript
levels to K562. This indicated that over-expression of MDM2
protein in SJSA-1 cells and MANCA cells correlated with high
levels of the mdm2-C transcript. Moreover, MANCA cells had
the highest ratio of mdm2-C to full-length transcript. This
outcome may be due to the mdm2 SNP309 G/G genotype that
drives transcription from the inducible P2 promoter.
In order to see if the mdm2 full-length to mdm2-C transcript
ratio influenced the p53 response, we compared the activation
of two p53 target genes, p21 and puma. We treated K562,
ML-1, SJSA-1 and MANCA cells with etoposide to initiate a
DNA damage response, and monitored p21 and puma
activation by qRT-PCR (Figure 1D). As expected, the p21 and
puma genes were not activated in p53-null K562 cells. In the
SJSA-1 and MANCA cells, which have wild-type p53 and high
MDM2, the p21 and puma genes demonstrated compromised
gene activation compared to the activation detected in ML-1
Human MDM2-C Activates p53-Independent Growth
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Figure 1.  An mdm2 splice variant transcript, mdm2-C is highly expressed in MDM2 over-expressing cells.  A. Quantitation
using Image J after northern blot analysis of RNA from untreated MANCA, SJSA-1, ML-1 and K562 cell samples. An mdm2 DNA
probe to exon 12 was PCR generated and radiolabelled with α 32P dCTP. Transcript levels were compared to K562 for basal
expression and normalized for RNA levels to gapdh. An average of four independent experiments is shown. Error bars indicate
standard error.
B. Schematic of mdm2 messages detected using a Taqman probe for exons 6 and 7 (6-7 probe) or forward primer for 4:10 and
reverse primer for 12 (4:10-12 primer) for mdm2-C.
C. qRT-PCR with 4:10 forward and exon 12 reverse vs. Taqman probe to exon 6 and 7 of mdm2 were performed to detect mdm2-C
and mdm2 (with exons 6 and 7) transcripts. The mdm2-C transcripts were detected via Syber Green and mdm2 (with exons 6 and
7) transcripts were detected via Taqman technology. Transcript levels were compared to K562 for basal expression and normalized
for RNA levels to gapdh. An average of three independent experiments is shown. Error bars indicate standard error.
D. qRT-PCR of RNA using Taqman technology from p53 target genes, p21 and puma after DNA damage treatment with 8μM
etoposide for 3 hours. Data from each cell line is presented as normalized to its own untreated control sample for fold activation and
normalized for RNA levels to gapdh. An average of three independent experiments is shown. Error bars indicate standard error.
doi: 10.1371/journal.pone.0077643.g001
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cells, with MANCA cells demonstrating the least p53 activity
(Figure 1D).
Mdm2 alternatively spliced products such as mdm2-B
increase after DNA damage [38–40]. To determine whether the
mdm2-C transcript was induced by p53, cells treated with
etoposide were analyzed by qRT-PCR for mdm2-C. The ML-1
cells responded to etoposide treatment with a robust increase
in mdm2-C transcript levels (Figure S2, red bar). Compromised
p53-mediated activation of mdm2-C was observed in the
SJSA-1 and MANCA cells similar to compromised activation
observed for puma (Figure S2 and Figure 1D). These data
show that p53 transcriptional activity was compromised in the
MDM2 over-expressing cells and their high basal levels of
mdm2-C (especially in MANCA cells) was p53-independent.
Validation of MDM2-C Specific Antibody
To determine if the high level of mdm2-C transcripts in
MDM2 over-expressing cells was translated into protein, we
generated an MDM2-C specific polyclonal antibody. We
immunized rabbits with a peptide sequence containing the
amino acid sequence of the human exon 4 to 10 splice junction
(Figure 2A). The peptide was highly immunogenic and the
antibody was validated for specificity using in vitro translated
MDM2 proteins in wheat germ extract. Both MDM2-C, and
MDM2-FL, can be translated in vitro into protein [3,41]. The
addition of 35S methionine into the system enabled us to rapidly
detect the specifically labeled MDM2 proteins using
autoradiography (Figure 2B). The 35S methionine labeled
MDM2-C and MDM2-FL proteins migrated on SDS-PAGE at
sizes previously determined (described as higher than the
predicted sizes of 36 kDa and 55 kDa, respectively) [41,42].
The slower mobility of MDM2 on SDS-PAGE has previously
been attributed to the large acidic domain of the protein[42].
To further validate the specificity of the MDM2-C antibody,
we carried out an immunoprecipitation experiment of the wheat
germ extract in vitro translated 35S radiolabeled MDM2-C and
MDM2-FL protein products. The MDM2 C410 polyclonal
antibody pulled down MDM2-C (Figure 2C, compare lanes 3
and 8) but not MDM2-FL (Figure 2C, compare lanes 4 and 9).
Furthermore, MDM2-C and MDM2-FL in vitro translated
proteins were immunoprecipitated using the MDM2 C410
polyclonal antibody and analyzed by western blot with MDM2
monoclonal antibody mix. Only the MDM2-C protein was
detected (Figure S3, compare lanes 2 and 3).
In order to more thoroughly address the differential migration
of the MDM2-C and MDM2-FL, we compared the immuno-
reactivity of in vitro translated proteins made in both rabbit
reticulocyte lysate (RRL) and wheat germ extract (WGE)
systems. When proteins are translated in vitro, they are post-
translationally modified by the factors represented in the cell
extract system. As predicted, the C-terminal monoclonal
antibody 4B11 detected MDM2-C and MDM2-FL isoforms while
the antibody 2A9, targeting the central region, detected only
MDM2-FL (Figure 2D, compare top and bottom panels for
lanes 1 and 3 versus lanes 2 and 4). Interestingly, the MDM2-C
produced in the mammalian RRL system resulted in high
expression of three differentially migrating species on SDS-
PAGE electrophoresis with one form co-migrating with MDM2-
FL at approximately 98 kDa (Figure 2D, compare lane 1 to lane
2). We further examined the potential post-translational
modifications of MDM2-C in human cells (and the migration of
MDM2-C at approximately 98 kDa) by utilizing a HeLa in vitro
translation system from Pierce (Figure 3A and 3B). Importantly,
in this system, we also detected a form of MDM2-C at
approximately 98 kDa. Our data clearly indicate that some of
the MDM2-C protein isoform produced in this human system
co-migrates with MDM2-FL. Thus providing evidence that the
detection of MDM2 by antibodies that can interact with the full-
length and spliced variant isoforms will result in at least some
co-migrating polypeptides on a western blot. Interestingly,
using the HeLa system, we for the first time, detected some
MDM2-C protein at the predicted molecular weight of 36 kDa
(Figure 3B lane 1).
MDM2-C protein is expressed endogenously
While alternatively spliced mdm2 messages have been
detected in cancers, there is no documentation on
endogenously produced polypeptides from such messages.
We compared the co-migrating nature of MDM2-C and MDM2-
FL using the variable immunoreactivity of human cancer cell
extracts probed with MDM2 C410 polyclonal antibody (for
detection of MDM2-C) to the same extracts probed with the
MDM2 pan-reactive mouse monoclonal 4B11 antibody (for the
detection of MDM2-C and MDM2-FL). High levels of MDM2
expression were observed in MANCA and SJSA-1 cell extracts
with 4B11 antibody (Figure 4A, lanes 9 and 10). MANCA cells
produced the highest expression of MDM2-C when detected
with C410 (Figure 4A, lane 1). The MDM2 C410 polyclonal
antibody barely detected MDM2-C in ML-1 cells (Figure 4A,
lane 3). However, it recognized MDM2-C protein in the cell
extracts from K562 cells, which are G/T genotype cells, as well
as in SJSA-1 cells that have a gene amplification (Figure 4A,
lanes 2 and 4). The expression of MDM2-C in ML-1 cells and
MANCA cells correlated with the basal transcription of mdm2
full-length and mdm2-C (compare Figure 1C to Figure 4A). For
reasons that remain unclear, a specific correlation between the
mdm2 transcripts and MDM2 protein isoforms was not
apparent for SJSA-1 cells and K562 cells. This may have been
due to the ratio of MDM2-FL protein to the spliced variant, and
subsequent E3 ubiquitin ligase-mediated degradation of MDM2
proteins that reduced protein stability.
The high expression of MDM2-C in MANCA cells suggested
that the protein would be clearly detectable in the cell
compartments. We examined the localization of endogenous
MDM2-C using cell fractionation methods (Figure 4B) and
spinning disk confocal microscopy (Figure 4C). Using
chromatin fractionation methods, we detected MDM2-C in the
cytoplasm and on the chromatin (Fig. 4Bi, lanes 1-3) and the
majority of the MDM2 isoforms detected with 4B11 were in the
cytoplasm (Fig. 4Bi, lanes 7-9). Exogenously expressed
MDM2-A and MDM2-B isoforms have previously been shown
to exhibit nuclear localization [43] despite the fact that the
regions encoding the MDM2 nuclear localization and export
signals are spliced out. Similarly, MDM2-C, which also has
these regions spliced out, localized to the cytoplasm and
Human MDM2-C Activates p53-Independent Growth
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nucleus of these hematopoietic cells (compare DAPI and
antibody stained area in Fig. 4Ci-iii probed with C410 and Fig
4Cvi-viii probed with pre-immune rabbit serum). MANCA cells
express high levels of wild-type p53 protein [14], and we
observed some co-localization of p53 and MDM2-C proteins in
the cytoplasm and nucleus as indicated by yellow merge color
(Fig. 4Cv). While the importance of co-localization is not
immediately understood, we believe that it is an important
observation. The red arrows point to strong antibody staining
that represents a consistent observation of protein localized to
discreet nuclear areas (Figs. 4Ciii and 4Cv). Since MANCA
hematopoietic cells are small and do not have much cytoplasm,
it was possible that what appeared cytoplasmic was on the
periphery of the nucleus. Therefore, we examined MDM2-C
localization in breast cancer epithelial cells and also observed
nuclear and cytoplasmic MDM2-C localization (Figure 5C).
MDM2-C increases with estrogen treatment and
localizes to distinct punctate foci in the cytoplasm and
nucleus of ER+ breast cancer cells
MDM2 is elevated after estrogen treatment of estrogen
receptor positive (ER+) breast cancer cells [36]. Furthermore,
mdm2 knockdown in estrogen treated breast cancer cells
results in a decrease in proliferation, thus providing evidence
Figure 2.  An MDM2-C specific antibody named C410, detects the MDM2-C protein.  A. Schematic of full length MDM2 (MDM2-
FL) and MDM2-C. The retained proteins’ biochemical functional domains are shown as color codes. The peptide sequence used as
an immunogen containing the splice junction of human MDM2-C is shown. Glycine (G) and Cysteine (C) residues were added to the
N-terminus of the peptide to facilitate conjugation to an immunoreactive protein, keyhole limpet hemocyanin (KLH).
B. 35S methionine was used as a radioactivity source to label in vitro translated proteins. In vitro translations of pcDNA3-mdm2-FL
and pcDNA3-P2mdm2-C using the TNT coupled wheat germ extract system. Resulting MDM2-FL and MDM2-C protein were
electrophoresed on a10% SDS-PAGE in a 5:1:1 ratio. The gel was transferred to a nitrocellulose membrane and exposed to film for
significant MDM2-C protein product detection. Wheat germ lysate without DNA was used as a negative control.
C. Immunoprecipitation of 35S methionine radioactive-labeled in vitro translated MDM2-FL and MDM2-C proteins using MDM2 C410
and pre-immune polyclonal serum antibodies. Protein ratios as shown in B were used in the pull down assay. Samples were
electrophoresed on a 10% SDS-PAGE gel transferred to a nitrocellulose membrane and exposed to film for protein detection. This
is representative of three independent experiments.
D. In vitro translated protein made in rabbit reticulocyte lysate (RRL lanes 1 and 2) were compared to protein translated in wheat
germ extract (WGE lanes 3 and 4). These proteins were detected with either antibody 4B11 (top panel) or 2A9 (bottom panel). HRP-
conjugated anti-mouse and anti-rabbit were used as secondary antibodies.
doi: 10.1371/journal.pone.0077643.g002
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for the importance of MDM2 in breast cancer cell growth. The
over-expression of MDM2 is associated with increased mdm2
spliced variant transcripts [3,24–28]. Therefore, we examined
the expression of MDM2-C protein in two ER+ breast cancer
cell lines, MCF-7 and T47D, possessing different genotypes for
mdm2 SNP309 (T/G versus G/G respectively) and p53 (wild-
type versus mutant respectively). We observed a slight
increase in MDM2-C protein after estrogen treatment of MCF-7
and T47D cells (Figure 5A lanes 2 and 4). The reason for the
difference in molecular weight of the MDM2-C isoforms might
be due to differences in post-translational modifications in
whole cell lysates. The pre immune polyclonal antibody serum
was used as a background control for the MDM2 C410
antibody and resulted in practically no protein detection (Figure
Figure 3.  Human MDM2-C migrates at 98 kDa.  Immunoprecipitation using MDM2 C410 and pre-immune polyclonal serum
antibodies with HeLa in vitro translated MDM2-C extracts using pre immune sera, MDM2 C410 and N-20 polyclonal antibodies.
Samples were electrophoresed onto a 10% SDS-PAGE gel in duplicate. A. One half was stained with coomassie blue for protein
detection. B. Samples from half of gel were transferred to nitrocellulose membrane and MDM2 was detected with 4B11 monoclonal
antibody. HRP-conjugated anti-mouse was used as secondary antibody. Arrows depict MDM2-C protein.
doi: 10.1371/journal.pone.0077643.g003
Human MDM2-C Activates p53-Independent Growth
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5A lanes 5-8). In addition, in T47D cells, the mdm2-C message
was increased two fold after estrogen treatment (data not
shown). We fractionated the cells and examined cytoplasmic
and chromatin fractions for MDM2-C protein (Fig. 5Bi for C410,
rabbit pre immune and mouse monoclonal 4B11 reactivity and
Fig. 5Bii for markers of fraction purity). The cytoplasmic fraction
did not contain chromatin as evident by the absence of
fibrillarin staining and each fraction showed some MDM2-C
reactive protein (Fig. 5Bi lanes 2 and 5). Interestingly, the
chromatin fraction from MCF-7 cells showed a strong MDM2-C
reactive species and less 4B11 reactive protein (Fig. 5Bi,
compare lanes 3 and 15).
To determine if estrogen treatment influenced the localization
of MDM2-C in MCF-7 and T47D cells, we carried out
immunoflouresence. The MDM2-C in MCF-7 was detected in a
pattern of diffuse and punctate cytoplasmic and nuclear
localization before and after estrogen treatment (Figs. 5Cii and
5Cvii). Despite very little detectable p53 in the MCF-7 cells
(Figs. 5Civ and 5Cix), the cytoplasmic p53 appeared to co-
localize with the MDM2-C, as co-staining was detected as a
yellow merge signal (Figs. 5Cv and 5Cx).
The visualization of MDM2-C by immunoflouresence in the
T47D cells, before and after estrogen treatment, displayed
similar staining to MCF-7 cells (Fig. 5Cxii and 5Cxvii).
However, T47D cells did not demonstrate co-localization of
mutant p53 and MDM2-C (Fig. 5Cxv and 5Cxx). The reason for
this difference in co-localization for MCF-7 cells and T47D cells
might lie in the fact that these cell lines have wild-type versus
mutant p53 proteins respectively. Many exogenously
expressed MDM2 spliced isoforms do not interact with p53
[43,44] and are known to splice out the majority of the p53-
binding domain [29]. We observed that T47D cells expressed
predominantly nuclear mutant p53 (Fig. 5Cxiv and 5Cxix) while
Figure 4.  High expression of endogenous MDM2-C protein in G/G mdm2 SNP309 MDM2 over-expressing cells.  A. Western
blot analysis of whole cell extracts from: MANCA, SJSA-1, ML-1 and K562 cells. MDM2-C protein levels were analyzed via MDM2
C410 polyclonal serum antibodies (C410, lanes 1-4) and total MDM2 was detected with the monoclonal 4B11 (lanes 9-12 and long
exposure for lane 12). Actin was used as a loading control. Pre immune polyclonal serum was used as a negative control. HRP-
conjugated anti-mouse and anti-rabbit were used as secondary antibodies. This is representative of three independent experiments.
Bi. MANCA cells were lysed either as whole cell extracts (WCE) or into cellular compartments- cytosolic (CYTO) and Chromatin
(CHR). Proteins were detected as in A. MDM2-C protein levels were analyzed via MDM2 C410 polyclonal serum antibodies (C410,
lanes 1-3) and total MDM2 was detected with the monoclonal 4B11 (lanes 1-9 and long exposure for lane 9).
Bii. Tubulin and Fibrillarin were used to show efficient cellular fractionation of extract.
C. Spinning disk confocal microscopy of MANCA cells. Cells were fixed, permeabilized and incubated with p53, MDM2 C410 and
pre-immune polyclonal serum antibodies. Slides were incubated with secondary Alexa-conjugated goat anti-rabbit and FITC-
conjugated goat anti-mouse. DAPI was used to stain the cell nuclei. Pictures were taken at 60X magnification. Arrows indicate
regions of Mdm2-C protein nuclear localization.
doi: 10.1371/journal.pone.0077643.g004
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MCF-7 cells express low levels of cytoplasmic and nuclear wild
type p53 [45].
MDM2-C is highly expressed in liposarcoma and breast
carcinoma tissues
High MDM2 expression is often observed in liposarcomas
and is currently used as a cancer diagnostic biomarker [46–49].
We were interested in examining if the C410 antibody would be
useful to examine MDM2-C as a liposarcoma biomarker in
Figure 5.  MDM2-C increases with estrogen treatment in ER+ Breast cancer cells and is located in the cytoplasm and
nucleus.  A. MCF-7 and T47D cells were grown and treated with 10nM estrogen (E2) for five days. Cells were lysed and proteins
were analyzed via western blot. MDM2 C410 polyclonal serum anti-rabbit antibody was used for protein detection. Pre-immune
polyclonal serum was used to detect background signal. HRP-conjugated anti-mouse and anti-rabbit were used as secondary
antibodies. Actin was used as a loading control. This is representative of three independent experiments.
Bi. MCF-7 and T47D cells were lysed for whole cell or chromatin fractionation extracts. 50μg of samples were resolved using 10%
SDS-PAGE and MDM2 C410 polyclonal sera (lanes 1 - 6) and MDM2 monoclonal antibody, 4B11 (lanes 13 - 18) were used for
protein detection. Pre immune was used to detect background signal (lanes 7 - 12). Secondary antibodies used were same as in A.
Bii. Tubulin and Fibrillarin were used to determine fractionation purity.
C. Spinning disk microscopy of MCF-7 and T47D cells. Cells were grown on coverslips and treated with 10nM E2 for five days. Cells
were fixed and incubated with p53 antibody and Mdm2 C410 polyclonal antibody for protein detection. Pre-immune serum was used
as a negative control for staining. Slides were incubated with secondary Alexa-conjugated goat anti-rabbit and FITC-conjugated
goat anti-mouse. DAPI was used to stain the nuclei. Cells were visualized at 60X magnification. Arrows depict MDM2-C localization
regions.
doi: 10.1371/journal.pone.0077643.g005
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patient samples. We used immunohistochemistry (IHC) to test
for MDM2-C expression in human liposarcoma tissue from
human patient samples. For two out of three sample sets
analyzed, positive staining for MDM2-C was observed
(representative image shown in Figure 6A). The pre immune
serum detected low background staining and when we
examined lipoma tissues, only low positive MDM2-C staining
was detected. We have begun similar studies using breast
cancer tissue micro-arrays and have detected MDM2-C in
invasive ductal carcinomas (Figure 6B). Using
immunohistochemistry, we observed a similar staining pattern
of positive tissues with MDM2 C410 and MDM2 4B11 antibody
(Fig. 6Bii and 6Bii) while mouse IGG did not result in tissue
staining (Fig. 6Biii).
MDM-C binds to full length MDM2 and other proteins in
vivo
Exogenously expressed MDM2-A and MDM2-B isoforms are
known to interact with MDM2-FL [33,43]. To evaluate if
endogenous MDM2-C in MANCA cells interacted with MDM2-
FL and other cellular proteins, we performed protein pull-down
assays with different MDM2 immunoreactive antibodies. We
assessed the extent to which other proteins interacted with the
endogenously expressed MDM2-C protein by culturing MANCA
cells in media containing 35S methionine and examined the co-
immunopreciptated radiolabeled proteins. Following MDM2-C
protein pull down using the C410 antibody (as compared to the
pre immune serum), we detected a number of proteins pulled
down, with an MDM2 band slightly above 98 kDa detected in
the western blot (Figure S4A).
The observation of many proteins co-immunoprecipitated
with MDM2-C was also detected with non-radioactive proteins
(Figures 7A and 7B). As described earlier, MDM2-C produced
in the Pierce HeLa in vitro transcription translation kit migrated
at approximately 98 kDa (Figures 3A and 3B, lanes 1-6).
Importantly, the 4B11 antibody detected MDM2-C at 98 kDa
and for the first time also at the predicted size of 36 kDa
(Figure 3B, compare lanes 1 and 2). Moreover both 98 and 36
kDa forms were immunoprecipitated by the polyclonal C410
and N-20 antibodies (Figure 3B lanes 5 and 6). This strongly
suggests that the C410 immuno-reactive MDM2-C isoform
detected in MANCA cell extracts co-migrates with MDM2-FL at
approximately 98 kDa. The SMP14 antibody epitope of
recognition lies within the MDM2 nuclear localization and
nuclear export signals absent in MDM2-C [29]. Interestingly,
western blot detection using MDM2 C410 polyclonal serum
antibody demonstrated that the SMP14 antibody co-
immunoprecipitated MDM2-C isoforms that migrated at sizes
above 98 kDa (Figure S4B lane 2- MDM2 C410 western blot).
The MDM2-C form migrating above 98 kDa is proposed to be
highly post-translationally modified forms of the MDM2-C
protein.
We made a preliminary identification of some of the
radiolabelled proteins immunoprecipitated with MDM2 C410
antibody from MANCA cells, by performing liquid
chromatography followed by tandem mass spectrometry
(LC/MS/MS) for six predominant gel band regions observed
after coomassie blue staining of the gel with non-radioactive
samples in Figure 7A (and Table S1). LC/MS/MS identified a
number of peptides, which corresponded to proteins with
biochemical functions such as: RNA splicing, transcription,
translation and metabolism. Based on “scaffold analysis” of
LC/MS/MS with a stringency of at least five peptides identified
with 95% probability, we identified 35 proteins (see Table S1
for protein sequence tags and accession gene symbols).
Examples of such proteins included: Nucleolin, Heat Shock
Cognate 71 Protein (HSP7C), Heat Shock protein HSP90β
(HS90B), probable ATP-dependent RNA helicase (DDX5), and
protein KIAA1967 (K1967). However, whether the proteins
pulled down maintain direct or indirect interactions with MDM2-
C, and the impact of MDM2-C binding on these proteins in vivo
is not known.
MDM2-C does not function in the canonical proteasome
MDM2 pathway
Prior work in BJ cells (human fibroblasts) showed that
exogenously expressed MDM2-A or MDM2-B isoforms
decrease cell proliferation with no associated degradation of
the p53 protein [28]. To determine the influence of MDM2-C on
cellular proliferation, we exogenously expressed MDM2-C in
p53-null H1299 cells in the presence and absence of
exogenously expressed p53. An increase in co-migrating 98
kDa MDM2-C protein (Figure 8A, lanes 3-8) or MDM2-FL
(Figure 8A, lanes 9-14) was detected with increasing amounts
of mdm2-FL or mdm2-C expressing plasmid DNA. The image J
values are shown in Figure 7A underneath the MDM2 4B11
and p53 probed blots. Importantly with MDM2-C expression,
the p53 protein levels did not substantially decrease (Figure
8A, lanes 3-8, middle panel-p53 with image J values
normalized to lane 2). This was in direct contrast to what was
observed with the increased addition of mdm2-FL expressing
plasmid, which resulted in substantial decreased p53 protein
levels (Figure 8A, lanes 9-14, middle panel-p53 with image J
values normalized to lane 2). This was seen most strikingly
when the highest concentration of the mdm2-FL transfected
plasmid was compared to mdm2-C (Figure 8A lane 8 vs. lane
14, middle panel – p53 levels). Image J quantification of the
p53 signal showed approximately 10 fold less p53 protein in
MDM2-FL expressing cells as compared to MDM2-C
expressing cells.
MDM2-A and MDM2-B isoforms are known to bind to MDM2-
FL, sequester it to the cytoplasm and promote p53 activation
[33,50]. We tested the effect of MDM2-C on p53 transcriptional
activity using a luciferase reporter assay in cells co-transfected
with p53 and either MDM2-C or MDM2-FL. Increasing MDM2-
FL protein reduced the p53 transcriptional activity, while
increasing MDM2-C protein did not (Figure 8B). These data
indicate exogenous expression of MDM2-C did not function in
the canonical p53 degradation pathway and did not significantly
inhibit p53 transcriptional activity.
The fact that MDM2-C did not function in a canonical MDM2
pathway caused us to assess the effect of MDM2-C on p53-
independent colony formation as an indicator of tumorigenic
properties. Colony formation assays were performed in human
p53-null H1299 lung carcinoma cells transiently transfected
with plasmids to express MDM2-C or MDM2-FL protein [7].
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Figure 6.  MDM2-C is highly expressed in liposarcoma and breast carcinoma tissues.  A. Immunohistochemistry of lipoma and
liposarcoma tissues using MDM2 C410 and pre-immune polyclonal serum antibodies. Biotinylated secondary antibody, ABC
Reagent and DAB from Vector Labs were used. Pictures were obtained at 20X and 40x magnification. H&E refers to Hematoxylin
and Eosin counterstaining. B. Breast tissue arrays (TMA-1008) were purchased from protein biotechnologies and automated
histology was performed at the Molecular Cytology Core Facility at Memorial Sloan Kettering Cancer Center. Antibodies MDM2
C410 and MDM2 4B11 were used for staining. Mouse IGG was used for negative staining. H&E refers to Hematoxylin and Eosin
counterstaining.
doi: 10.1371/journal.pone.0077643.g006
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Cells were seeded at low cell number into drug selection
medium and allowed to grow for a period of two to three weeks.
After the prolonged incubation time, cells expressing MDM2-C
formed more colonies as compared to cells expressing MDM2-
FL or vector control (Figure 8C). Quantification of the data
showed that H1299 cells expressing MDM2-C protein had the
greatest number of colonies (Figure 8D). Validation of MDM2-C
and MDM2-FL protein expression was observed by western
blot analysis from the transfected H1299 cells after puromycin
selection (data not shown).
Discussion
We report here that in human cancer cell lines that over-
express MDM2, we detect high expression of the mdm2-C
 transcript and MDM2-C protein. We have identified an
immunogenic region of human MDM2-C protein, which is a
peptide from the exon 4 to exon 10 splice junction. This peptide
was used for the development of a rabbit polyclonal MDM2-C
specific antibody that was able to specifically detect
exogenously and endogenously expressed MDM2-C protein in
human cell lines and tissues. We found that MDM2-C protein
co-migrates with MDM2-FL at an aberrantly high molecular
weight. The cause for MDM2 isoforms migrating higher than
their calculated molecular weight has remained a highly
debated area. There have been some suggestions that this is
due to post-translational modification of MDM2. We detected
three different isoforms of MDM2-C produced in RRL (that
were not detected with central region antibody) indicating a
high likelihood of variable post-translational modifications of the
Figure 7.  Human MDM2-C interacts with a variety of proteins in vivo.  Immunoprecipitation from MANCA whole cell extracts
using MDM2 C410 and pre-immune polyclonal serum antibodies antibodies. Samples were electrophoresed onto a 10% SDS-PAGE
gel in duplicate. A. One half was stained with coomassie blue for protein detection and protein bands from A were excised for
analysis via LC/MS/MS. B. Samples from half of gel A were transferred to nitrocellulose membrane and MDM2 protein was detected
using the MDM2 monoclonal antibody mix (4B2, 2A9, 4B11). A. Bracket represents region where bands were cut out for LC/MS/MS
analysis. B. Arrows depict MDM2-C protein.
doi: 10.1371/journal.pone.0077643.g007
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MDM2-C protein. This is especially important because while it
has been documented that MDM2 isoforms run above their
predicted molecular weight, it has not been clear how much of
the change is dependent on variable post-translational
modifications. Our data indicate that MDM2-C is differently
post-translationally modified in RRL and WGE systems (Figure
2D) as well as in the human HeLa systems from Pierce (Figure
3B); and that MDM2-C can migrate at approximately 98 kDa,
which is the same mobility as MDM2-FL (Figure 2D). This has
great implications for analysis of MDM2 western blots and
suggests that in human systems, it is difficult to identify the
variable MDM2 isoforms in SDS-PAGE. The development of
monoclonal antibodies to human MDM2-C and other MDM2
splice isoforms will assist in the detection of oncogenic
biomarkers for multiple types of cancers.
The functions of MDM2-A and MDM2-B isoforms have been
determined using exogenous protein expression. However, few
studies have been carried out on MDM2-C. MANCA cells
expressed a high ratio of mdm2-C to mdm2-FL transcript and
high levels of MDM2-C protein (Figures 1C and 4A). We
identified high levels of mdm2-C transcript in SJSA-1
osteosarcoma cells that have 25 copies of the mdm2 gene [37]
(Figure 1C), but detected very little MDM2-C protein (Figure
4A). The reason for this may lie in the almost one to one ratio
of mdm2-C to mdm2-FL transcripts. It is possible that the
higher levels of MDM2-FL protein result in low MDM2-C protein
levels because MDM2-FL is acting as an E3 ubiquitin ligase for
Figure 8.  MDM2-C has p53-independent transformation activity.  A. Analysis of exogenously expressed MDM2-FL or MDM2-C
in H1299 cells with simultaneous expression of p53. Increasing amount of pcDNA3-mdm2-FL and pcDNA-P2mdm2-C plasmid
DNAs were transiently transfected with a constant amount of SN3 plasmid (p53) into H1299 p53-null cells. PGL2 Basic plasmid was
used as a DNA normalizer. Cells extracts were prepared 48 hours after transfection and analyzed for protein expression by western
blot analysis using the Mdm2 monoclonal antibody mix (4B11) and p53 monoclonal antibody mix (240, 1801, 421). Actin was used
as a loading control. HRP-conjugated anti-mouse and anti-rabbit were used as secondary antibodies. This is a representative of
three independent experiments.
B. 48 hours after transfection, cells were lysed and protein extracts were utilized in a luciferase assay reaction. Samples were
compared to PGL2 Basic plasmid and normalized for amount of protein. An average of three independent experiments is shown.
Error bars represent standard error.
C. Colony formation assay in H1299. Cells were transiently transfected with the plasmid pBaBe-puro-mdm2-FL or pBaBe-puro-
mdm2-C and after 24 hours, 2000 cells were plated into media (RPMI with 2ug/ml puromycin). Cells were allowed to grow for 3
weeks. Picture represents one experiment. Two experiments were carried out in duplicates.
D. Colony counts after colony formation assay. An average of two experiments carried in duplicates is shown above. Error bars
represent standard error. * Asterisks represent p-value compared to vector control.
doi: 10.1371/journal.pone.0077643.g008
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MDM2-C. This may account for the difference in MDM2-C
protein levels observed in different cell types as suggested by
the comparison of MANCA and SJSA-1 cells.
Mice humanized as G/G for the mdm2 SNP309 in two
murine mdm2 alleles produce a two and a half fold increase in
mdm2 transcript. This causes an increased cancer risk and
changes the mutant p53 associated tumor spectrum including
mammary adenocarcinoma [23]. We observed that SJSA-1
cells and MANCA cells (which are both resistant to cellular
stress) [32] showed compromised induction of p21 and puma
transcription after DNA damage (Figure 1D). We also saw high
levels of MDM2-C transcript and protein in the mutant p53
expressing T47D breast cancer cell line (Figure 5) [45]. This
suggests that the levels of individual mdm2 transcripts
influence the wild-type p53 response as well as p53-
independent cell survival pathways.
MDM2 is over-expressed in over 30% of sarcomas, 80% of
well-differentiated liposarcomas (WDLPS), and 60% of myxoid
liposarcomas [51]. Using immunohistochemistry, we observed
high expression of MDM2-C in liposarcoma and breast
carcinoma patient tissues, and less expression of MDM2-C in
lipoma and normal breast hyperplasia tissues (Figure 6). This
suggests that MDM2-C may be used as a prognostic biomarker
for cancers that have gained an MDM2 oncogenic pathway.
Exogenously expressed MDM2 isoform proteins localize to
the nucleoplasm [43] and cytoplasm [28,40]. We found
endogenous MDM2-C protein localized to the cytoplasm and
nucleus of human cancer cells by immunofluorescent staining
(Figures 4 and 5). We detected MDM2-C as punctate,
suggesting that unlike the other MDM2 isoforms, MDM2-C
might function in an alternate pathway related to its novel type
of cellular distribution. This distribution pattern requires further
study. Specific immunoprecipitation of MDM2-C from MANCA
whole cell extract followed by Liquid Chromatography with
tandem Mass Spectroscopy (LC/MS/MS) analysis allowed for a
preliminary identification of co-associated proteins involved in
splicing and translation (work in progress). However, MDM2
sequence tags were not identified most likely due to extensive
post-translational modification of the protein in our samples.
We hypothesize that MDM2-C is performing a function that is
distinct from other MDM2 isoforms, which relates to its binding
partners and cellular localization. It is possible that MDM2-C
influences the splicing and translation of factors involved in
growth promotion. The MDM2-C protein isoform maintains the
RNA binding region of full length MDM2 [52–55]. Future
experiments are needed to examine the RNA binding ability of
MDM2-C. It is possible that we detected MDM2-C interacting
with RNA binding proteins solely because such proteins were
bound to an RNA transcript attached to MDM2-C. An
alternative is that the mdm2-C transcript also has gene
expression regulatory properties [56,57].
Increased MDM2 expression causes the degradation of wild-
type p53 in a proteasome-dependent manner that requires
three domains of MDM2 [7–10,58–62]. Splice variant isoforms
of MDM2 do not degrade p53 although they retain the RING
finger domain [29]. Simultaneous expression of MDM2-C with
wild-type p53 in the p53-null H1299 cells demonstrated that
wild-type p53 was not efficiently degraded by MDM2-C. The
reason for this may lie in the fact that MDM2-C is lacking
portions of the p53-binding domain critical in facilitating the
MDM2-p53 interaction, which is important for p53 degradation
[63]. Most MDM2 variant isoforms documented are unable to
bind to p53 [43,44]. Therefore it is not surprising that MDM2-C
did not substantially induce p53 degradation and appears to
function through a p53-independent pathway.
MDM2 can promote cell proliferation independently of p53
and serve as a cancer biomarker [36,64]. Our data support the
involvement of MDM2-C in p53-independent cell proliferation.
The exogenous expression of MDM2-C in p53-null H1299 cells
resulted in increased colony formation. In the ER+ breast
cancer cell lines, we also observed an estrogen-dependent
increase in MDM2-C protein. This suggests that MDM2-C could
be a survival factor for ER+ cells following exposure to
estrogen. Examining the levels of MDM2-C in cancer tissues
could help identify cancers that are driven by p53-independent
pathways. Our data implicate that MDM2-C has roles in p53-
independent activation of cell proliferation. Two major cancer
related proteins that functionally interact with MDM2 and are
involved in cell proliferation and cell cycle control, are E2F and
RB [65–67]. Whether MDM2-C protein functions in the E2F/RB
pathway, other growth pathways, or participates in the
regulation of RNA processing are questions that remain to be
addressed. Our findings with MDM2-C open up a new avenue
to explore in terms of cancer prevention and prognosis.
Materials and Methods
Plasmids
Human MDM2 expression plasmid, pcDNA3.1-F-hdm2 was a
generous gift from Dr. Carol Prives; PGL2-Basic; p21-
Luciferase (p21 p53 responsive elements) [68]; SN3 (p53) [69];
pBabe-puromycin (pBabe-puro) plasmid was a generous gift
from Dr. Xuejun Jiang. For HeLa in vitro translation we used
vector pT7CFE1-CGST-HA-His-GFP (Pierce/ Thermo
Scientific).
Plasmid DNA Cloning
pcDNA3-F-hdm2 was used as a swap backbone to generate
the clone containing exons-2, 3, 4, 10, 11 and 12 for
pcDNA3.1-P2mdm2-C plasmid. Restriction enzymes- BamHI
and EcoRI (New England Labs) were used for this swap to
sub-clone exons 2-12 for mdm2-C into the pcDNA3-F plasmid
retaining just the end of exon 12. DNA sequences for mdm2-FL
and mdm2-C from the pcDNA3.1 vector were sub-cloned with
enzymes- BamHI and EcoRI (New England Labs), into the
pBabe-PURO vector. The mdm2-C coding region was inserted
into the TOPO vector via TA cloning and sub-cloned from the
TOPO-mdm2-C plasmid using restriction enzyme, NdeI into the
IRES pT7 vector plasmid pT7CFE1-CGST-HA-His-GFP.
Cell culture
The tissue culture cells used in this study were: K562, ML-1,
MANCA, SJSA-1, H1299, T47D and MCF-7. K562, SJSA-1,
H1299, MCF-7 and T47D cells were purchased from American
Type Culture Collection (ATCC); ML-1 cells were a generous
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gift from Michael Kastan [70]; MANCA cells were a generous
gift from Andrew Koff [71]. Tissue culture cells were grown in
RPMI 1640 media (Mediatech) or DMEM media (CellGro),
containing 10% fetal bovine serum (FBS, Gemini) and 50U/ml
penicillin and 50µg/ml streptomycin-pen-strep (Mediatech).
Estrogen treatments were done using phenol red-free DMEM
and 10% charcoal stripped FBS.
Drug treatments
Drugs used in this study include: DMSO, etoposide, estrogen
(17β Estradiol, E2): all drugs were purchased from Sigma.
Cells were treated for 3 hours at the concentration of 8µM of
Etoposide and three or five days at 10nM E2.
RNA isolation and quantitative RT-PCR
Cells were centrifuged at 1,100 rpm for 6 minutes at 4°C,
washed twice with ice-cold phosphate buffered saline (PBS),
and cells were frozen at -80°C overnight. The RNA was
isolated using QIAshredder columns and the RNeasy Mini Kit
(Qiagen) following manufacturer’s protocol and the resulting
RNA was stored at -80°C. 5µg of RNA was used for cDNA
synthesis using the High Capacity cDNA Archive Kit reagents
and protocol (Applied Biosystems), where the RT master mix
(containing RT buffer, dNTPs, random primers and MultiScribe
reverse transcriptase) along with the RNA was incubated at
room temperature for 10 minutes and then at 37°C for 2 hours.
cDNA was stored at -20°C. Gene transcripts were amplified by
quantitative PCR (qRT-PCR) with primer probes for puma
(Hs00248075_m1), mdm2 (Hs00242813_m1), p21
(Hs00355782_m1) and gapdh (4333764) from Applied
Biosystems Assays on Demand primers. In addition, primers to
mdm2-C (exon 4:10 Forward:
GAAAGAGGATCTTGATGCTGGTGTA and exon 12 Reverse:
GGGGGATTCATTTCATTGCATG- both in the 5’ to 3’ direction)
were used in a Syber Green qRT-PCR reaction to quantify
mdm2-C transcripts. 150ng of cDNA was combined with
Taqman Universal Master Mix and qRT-PCR was carried out
following the program: one cycle, 2 minutes, 50°C; one cycle,
10 minutes, 94°C; and 40 cycles, 15 seconds, 94°C and 1
minute 60°C in a 7500 Sequence Detection System (Applied
Biosystems).
Preparation of Radioactive probe
Plasmid DNA was combined with Taqman Universal Master
Mix and primers flanking regions of mdm2 exons 12 (forward:
TTCGTGAGAATTTGGCTTCCT, reverse:
GGCAGGGCTTATTCCTTTTC- both in the 5’ to 3’ direction) for
PCR in a GeneAmp 5400 (Perkin Elmer, Waltham, Mass). The
amplification steps were as follows: one cycle, 5 minutes 50°C,
10 minutes, 94°C; 35 cycles, 30 seconds, 94°C, 30 seconds,
58°C, and 2 minutes 72°C; and 10 minutes, 72°C. The resulting
PCR product was purified using the QiaQuick PCR Purification
Kit (QIAGEN). 25ng of PCR template was used for Random
labeling with the High Prime Random Labeling Kit (Roche) and
Easy Tag α-32P dCTP (Perkin Elmer) was used as the
radioactivity source. The resulting probe was cleaned using
SephadexTM G-50 DNA Grade Nick Columns (GE Healthcare)
and the count per minute (CPM) was measured using a
Scintillation counter (Perkin Elmer).
Northern blot analysis
mRNA samples were purified from total RNA using the
Oligotex mRNA Mini Kit (QIAGEN). Total RNA samples were
separated using a 1.0% denaturing formaldehyde agarose gel
followed by a 10X SSC capillary action transfer onto a
BrightStar-Plus positively charged Nylon membrane (Ambion)
no more than 6 hours. RNA was cross-linked to the membrane
via Ultra Violet exposure at the optimal setting for 1 minute.
The membrane was then pre-hybridized in formamide pre-
hybridization/hybridization solution for 3 hours at 42°C after
which the probe (heated at 95°C for 10 minutes and placed on
ice to cool) was added to the membrane for hybridization over
night. The membrane was then washed at different
stringencies (2X SSC/ 0.1%; 0.2% SSC/ 0.1% SDS and 2X
SSC). Autoradiography was achieved by exposing the
membrane to Kodak BioMax XAR Films (KODAK) at room
temperature and at - 80°C with screen.
In vitro transcription/ translation
100-1000ng of linearized pcDNA3-mdm2-FL or pcDNA3-
mdm2-C plasmid DNA was mixed with components of the
wheat germ extract kit or rabbit reticulocyte extract kit
(Promega) and allowed to sit at 30°C for 90 minutes.
Radiolabelled 35S Methionine (Promega) was used as a
radiolabel source. The resulting protein was resolved on a 10%
polyacrylamide gel. HeLa Cell In vitro translation in 1-Step
Heavy Protein IVT system (Piece/Thermo Scientific) -1-2μg of
pT7CFE1-mdm2-C (or pT7CFE1-CGST-HA-His-GFP) was
mixed with the components of the HeLa cells lysate in vitro
translation system and placed at 30°C for 8-24 hours. The
samples were centrifuged at 14,000 x g for 5 minutes and the
supernatant was frozen at -80°C.
Radioactive labeling of endogenous proteins
MANCA cells were grown in 10% FBS/RPMI (Mediatech)
minus Methionine supplemented with > 1000mCi of 35S
Methionine. Cells were collected and lysed after 24 hours.
Cellular protein extracts- Whole cell extracts
Cells were pelleted at 1,100 rpm for 6 minutes at 4°C,
washed twice with ice-cold PBS and re-suspended in 1.5-2X
packed cell volumes of 1X lysis buffer (0.1% TritonX-100,
50mM Tris.Cl PH-7.5, 15mM EGTA, 100mM NaCl, 1 mM
PMSF, 8.5 μg/ml Aprotinin and 2 μg/ml Leupeptin). The cell
suspension was vortexed at intervals for 30 minutes on ice to
lyse the cells and centrifuged at 13,000 rpm for 20 minutes at
4°C. The supernatant was stored at -80°C.
Chromatin Fractionations
Cells were pelleted at 1100 rpm for 7 minutes at 4°C and
washed three times with ice- cold phosphate buffered saline
(PBS). Cells were suspended in Buffer A (10 mM HEPES pH
7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34M Sucrose, 10% glycerol,
1mM DTT, 0.5 mM PMSF, 2µg/ml Leupeptin, 8.5µg/ml
Human MDM2-C Activates p53-Independent Growth
PLOS ONE | www.plosone.org 14 October 2013 | Volume 8 | Issue 10 | e77643
Aprotinin) + 0.1% Triton X-100. Incubated on ice 5 minutes.
Spun down cells 3600 rpm for 5 minutes at 4°C. Spun down
supernatant for an additional 5minutes at 13,000 rpm at 4°C to
clarify (S1 Fraction). Washed pellet 2 times with Buffer A
spinning down at 3600 rpm for 5min at 4°C. Resuspended
nuclei pellet in Buffer B (3 mM EDTA, 0.2 mM EGTA, 0.5 mM
PMSF, 2µg/ml Leupeptin, 8.5µg/ml Aprotinin). Incubated on ice
30 minutes with vigorous vortexing every 5 minutes. Spun
down 4000 rpm for 5 minutes at 4°C. The supernatant is
nuclear soluble proteins (S2 Fraction) and the pellet is enriched
in chromatin. Washed pellet 2 times with Buffer B.
Resuspended pellet (P3 Fraction) in RIPA buffer and sonicated
3 times 30 seconds/30 seconds rest on ice. Froze samples at
-80°C.
Western blot analysis
Protein samples were prepared in 4X protein sample buffer
(4X NuPAGE Lithium Dodecyl Sulphate buffer, 20mM DTT).
Samples were heated at 70°C for 10 minutes after which
100mM Iodoacetamide (Sigma-Aldrich) was added to prevent
re-ligation of disulfide bridges between polypeptides. All
samples were separated via 10% SDS-PAGE followed by an
electro-transfer to nitrocellulose membrane. The membrane
was blocked in 5% non-fat milk solution of 1XPBS/ 0.1%
Tween 20 and was probed overnight at 4°C. Washes were
done with 1XPBS/0.1% Tween 20 solution. Secondary anti-
mouse or anti-rabbit antibody (Sigma) was applied to the
membrane for 1hr at room temperature and the membrane was
washed three times. Protein signal was visualized by
chemiluminescence using the Super signal kit (Pierce) and
detected after exposure for autoradiography to Hyblot CL films
(Denville Scientific).
Antibodies
p53- mouse anti-human monoclonal supernatant antibodies
mix- 1801, 421 and 240 (N-terminus, Central and C-terminus
regions respectively) [72], DO-1- mouse anti-human
monoclonal antibody (Santa Cruz); Mdm2- mouse anti-human
monoclonal supernatant antibodies mix- 4B2, 2A9 and 4B11
(N-terminus, Central and C-terminus regions respectively) [42],
SMP14- mouse anti-human monoclonal antibody (Sigma);
N20- mouse anti-human polyclonal antibody (Santa Cruz);
MDM2-C- rabbit anti-human polyclonal pre-immune serum and
MDM2 C410 immune polyclonal serum antibody
(Biosynthesis); Actin- rabbit anti-human polyclonal antibody
(Sigma); fibrillarin (Abcam), tubulin (Sigma).
Immunoprecipitation
In vitro translated protein products or whole cell extracts of
MANCA were incubated with 1-2μg (SMP14 or N20) or 5-10μl
(serum) primary antibody (MDM2 C410 serum, pre-immune
serum) in 1X lysis buffer (0.1% Triton-X w/v, 50mM Tris.CL
(P.H 7.5), 15mM Ethylene Glycol Tetraacetic Acid-EGTA,
100mM Sodium Chloride-NaCL, 1mM Phenylmethanesulfonyl
Fluoride-PMSF, 2μg/ml Leupeptin and 10.3μg/ml Aprotonin).
The mixture was placed at 4°C over night. The next day,
protein-A sepharose beads were added for 3 hours. The
protein-Antibody-beads mixture was spun down at 3000 rpm
for 2 minutes and washed 3X with 1X PBS/0.1% TWEEN 20.
The complex was re-suspended in 30μl 1X Protein sample
buffer with 20mM DTT. Samples were heated at 70°C for 10
minutes and 1mM Iodoacetamide (Sigma) was added and
resolved on a 10% acrylamide gel.
Immunofluorescence
Cells were seeded onto glass cover slips at 10% confluency
and after indicated treatments, washed once with 1X PBS and
fixed with 4% paraformaldehyde in 1XPBS for 15 minutes at
room temperature. MANCA cells were spun down onto poly-
lysine covered cover slips and treated Slides were washed
three times with 1X PBS, permeabilized with 0.5% Triton-X-100
in 1X PBS/1% FBS for 10 minutes at room temperature and
washed three times with 1X PBS/1% FBS. The cells were
incubated for 1 hour at room temperature with 1:200 dilution of
rabbit anti-human MDM2 C410 serum or rabbit anti-human pre-
immune serum, p53 mouse anti-human monoclonal DO-1. The
slides were washed three times with 1XPBS/1% FBS,
incubated with 1:200 dilution of Alexa-conjugated goat anti-
rabbit (Invitrogen) and FITC-conjugated goat anti-mouse
(Jackson ImmunoResearch) secondary antibodies, and
washed again three times with 1XPBS/1% FBS. Coverslips
were then mounted onto slides using Vectashield mounting
medium containing 4’, 6-diamidino-2-phenylindole (DAPI) to
visualize the nuclei. Images were collected with a Nikon
fluorescent microscope at 60X magnification.
Spinning disk confocal microscopy
Cells were visualized using spinning disk confocal
microscope. All confocal images were captured with the 60X
objective. Images were visualized and captured under different
channels: rhodamine (red), FITC, and ultra violet light (Blue for
DAPI).
Immunohistochemistry
Paraffin embedded slides were de-paraffinized with Xylene
(2x 3 minutes) and Xylene:100% Ethanol (3 minutes). The
slides were then hydrated in 100% Ethanol (2x 3 minutes, 95%
Ethanol (3 minutes), 70% Ethanol (3 minutes) and 50% Ethanol
(3 minutes). Slides were rinsed in water and placed in the
antigen retrieval buffer (10mM Tris base, 1mM EDTA and
0.05% Tween 20 PH 9.0) and boiled for 20 minutes after the
solution had come to boiling. The slides were rinsed in cold
water and washed 3x 5 minutes in 1X wash buffer (1XPBS/
0.025% Triton X-100). Slides were blocked in blocker solution
from the Vectastain ABC kit (Vector Labs) for 1 hour at room
temperature. The slides were rinsed in 1X wash buffer 3x 5
minutes. Primary antibody – C410 serum and pre-immune
polyclonal serum were diluted to 1:100 in 1X PBS/1%BSA and
incubated over night at 4°C. The next day, slides were rinsed
3x 5 minutes in 1X wash buffer. The secondary antibody
mixture (Vector Labs) was diluted in blocking solution and
incubated fro 45 minutes at room temperature. The slides were
washed 3x for 5 minutes in the wash buffer. The slides were
developed for approximately one minute per slide using the
Peroxidase Substrate kit DAB (Vector Labs). The slides were
rinsed with water immediately when staining began to develop.
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Slides were counterstained with Hams modified Hematoxylin
and Eosin [73] and washed in water 2x 5 minutes. The slides
were then dehydrated as follows: 2x 95% Ethanol, 2x 100%
Ethanol and 2x 100% Xylene. The slides were then mounted
with Permount solution [73] and visualized under the Nikon
bright upright microscope and pictures are taken at 20X
magnification. Breast tissue arrays were purchased from
“Protein Biotechnologies Ramona, CA”. The “Molecular
Cytology Core Facility” at Memorial Sloan Kettering Cancer
Center performed histology.
Transfection
Approximately 2-6x105 cells were plated per well in 6-well
plates or at 50% confluence into 10cm plates per transfection.
Cells were treated with Lipofectamine 2000 (Invitrogen) as per
manufacturers’ instruction. 10ng of SN3 plasmid and
10-1000ng pcDNA3.1-Fhdm2 or 10-1000ng pcDNA3.1-
P2mdm2-C, were co-transfected with 10ng of SN3 [69] plasmid
and p21-luciferase plasmid [68]. PGL2 plasmid was used as a
DNA control.
Luciferase assay
Cells were co-transfected with SN3, p21-luciferase reporter
plasmid and pcDNA3.1-Fhdm2 or pcDNA3.1-P2mdm2-C. 48
hours after transfection, cells were lysed as stated above and
assayed using the luciferase reporter assay (Promega) and
measured via Luminoskan. Samples were normalized for the
amount of protein.
Trypan Blue Staining
Cells are trypsinized and spun down at 1100rpm for 5
minutes. The cell pellet was re-suspended in serum-free
DMEM and 0.4% Trypan blue dye (Sigma) was added to the
cells at a 1:6 dilution ratio. The dye and cells mixture was
allowed to sit at room temperature for 5 minutes and the total
numbers of cells as well as the number of blue cells were
counted.
Colony formation assay
H1299 cells were co-transfected with or without 10ng of SN3
plasmid and 400ng of pBaBe-mdm2-FL or pBaBe-puro-mdm2-
C plasmids. Five hours after transfection, the media was
changed to complete RPMI/10%FBS or DMEM/10% FBS. 24
hours later cells were diluted and 2000 cells were plated into
media with 2µg/ml puromycin on 10cm plates and allowed to
grow for 2-3 weeks. Colonies were stained with methylene blue
(Sigma-Aldrich) and counted.
Coomassie staining
Acrylamide gels were rinsed 3X with Mill-Q water for 15
minutes each and stained for an hour using Gel Code Blue
(Thermo Scientific) as per manufacturer’s suggestions.
Liquid Chromatography tandem Mass Spectrometry (LC-
MS/MS).  After MDM2 C410 immunoprecipitation and
coomassie staining of co-immunoprecipitated proteins on the
SDS-PAGE, protein bands were excised and trypsin was
utilized for sample digestion. All samples were subjected to LC-
MS/MS and the resulting data was uploaded onto a proteome
software program, scaffold 3. Scaffold 3 analyzes the MS/MS
data and collates the information in a table format giving the
identified peptides, their corresponding proteins, biological
functions and classification based on biological function. The
program identifies a protein based on the peptides observed
and their frequency. The data obtained was put in a table
format according to the frequency of peptides observed and the
protein sequence tags detected. The analysis was performed
by the Mass Spectrometry facility of the Proteomics and
Microchemistry Core Facility at Memorial Sloan Kettering
Cancer Center (MSKCC).
Supporting Information
Figure S1.  MDM2 over-expressing cells have high mdm2
transcript levels. Northern blot quantitation of total RNA from
untreated K562, ML-1, SJSA-1 and MANCA, cells. RNA
samples were electrophoresed onto a 1% denaturing
formaldehyde agarose gel and transferred to a nylon
membrane. The northern blot was probed with an exon 12-
specific probe for mdm2 and exposed to film for transcript
detection. α 32P dCTP was used as a radioactivity source for
the probe labeling. GAPDH was used as a normalizer for RNA
levels. Relative mdm2 message for lanes 1 - 4 was an average
of 1, 2.2, 6 and 4 respectively shown in Figure 1.
(TIF)
Figure S2.  Etoposide activated transcription of mdm2 is
compromised in MDM2 over-expressing cells. qRT-PCR of
RNA from mdm2-C genes using syber green technology after
induction of p53 via 8μM etoposide for 3 hours. Each cell line
was normalized to its own control sample for fold activation and
gapdh for RNA levels. An average of three independent
experiments is shown. Error bars indicate standard error.
(TIF)
Figure S3.  MDM2 C410 antibody is specific to MDM2-C
protein. Immunoprecipitation of in vitro translated MDM2-FL
and MDM2-C proteins using MDM2 C410 and pre-immune
polyclonal serum antibodies. MDM2 monoclonal antibody mix
(4B2, 2A9, 4B11) was utilized for protein identification. Wheat
germ lysate without plasmid DNA was used as a negative
control. HRP-conjugated anti-mouse and anti-rabbit were used
as secondary antibodies. This is a representative of three
independent experiments. Arrow represents MDM2-C band.
(TIF)
Figure S4.  MDM2-C interacts with MDM2-FL and other
cellular proteins in vivo. A. Immunoprecipitation of 35S
Methionine radioactive labeled MANCA whole cell extracts
using Mdm2 C410 and pre-immune antibodies. Samples were
electrophoresed on a 10% SDS-PAGE gel, transferred to
nitrocellulose membrane and exposed to film for protein
detection. Arrows represent MDM2 protein bands.
B. Immunoprecipitation from MANCA whole cell extract using
MDM2 antibody, SMP14. Samples were electrophoresed on a
10% SDS-PAGE gel, transferred to a nitrocellulose membrane
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and probed with MDM2 C410 polyclonal serum antibody.
Immunoprecipitation was also performed with the MDM2 C410
and pre immune antibodies. Samples were electrophoresed on
a 10% SDS-PAGE gel, transferred to a nitrocellulose
membrane and probed with MDM2 4B11 monoclonal serum
antibody. The membrane was sequentially re-probed with
MDM2 2A9 monoclonal antibody. HRP-conjugated anti-mouse
and anti-rabbit were used as secondary antibodies. Arrows
represent MDM2-C interacting protein bands.
(TIF)
Table S1.  List of proteins identified by LC/MS/MS and their
protein sequence tags. After LC/MS/MS was carried out by
the Memorial Sloan-Kettering Cancer Center Proteomics and
Microchemistry Core Facility we used “scaffold analysis” of the
identified peptides. We employed parameters with a stringency
of at least five peptides with 95% probability, which identified
35 proteins.
(XLS)
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